Rockwell Medical (NASDAQ: RMTI) and Zynex Inc. common stock (OTCMKTS:ZYXI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.
Insider & Institutional Ownership
21.2% of Rockwell Medical shares are held by institutional investors. Comparatively, 0.0% of Zynex Inc. common stock shares are held by institutional investors. 18.2% of Rockwell Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Rockwell Medical and Zynex Inc. common stock’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Rockwell Medical||$57.30 million||4.76||-$25.92 million||($0.51)||-10.33|
|Zynex Inc. common stock||$23.43 million||4.84||$7.36 million||$0.22||15.55|
Zynex Inc. common stock has lower revenue, but higher earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than Zynex Inc. common stock, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Rockwell Medical has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. Comparatively, Zynex Inc. common stock has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.
This table compares Rockwell Medical and Zynex Inc. common stock’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Zynex Inc. common stock||33.24%||356.96%||128.90%|
This is a summary of current recommendations for Rockwell Medical and Zynex Inc. common stock, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Zynex Inc. common stock||0||1||0||0||2.00|
Rockwell Medical presently has a consensus price target of $11.00, indicating a potential upside of 108.73%. Given Rockwell Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Rockwell Medical is more favorable than Zynex Inc. common stock.
About Rockwell Medical
Rockwell Medical, Inc. operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment. It also provides Calcitriol, a generic active vitamin D injection, which is indicated for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, Renalpure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubings, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its concentrated dialysate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. The company's target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1995 and is based in Wixom, Michigan.
About Zynex Inc. common stock
Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.